Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Purple Biotech Ltd. - American Depositary Shares (NQ:PPBT)

0.7713 -0.6487 (-45.68%)
Streaming Delayed Price Updated: 11:18 AM EDT, Sep 4, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 42,242,238
Open 0.8793
Bid (Size) 0.7710 (1)
Ask (Size) 0.7713 (12)
Prev. Close 1.420
Today's Range 0.7300 - 0.9153
52wk Range 1.270 - 13.95
Shares Outstanding 17,210,574
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Which stocks are gapping on Thursday?
Traders are paying attention to the gapping stocks in Thursday's session. Let's dive into which stocks are experiencing notable gaps. 
Via Chartmill
Purple Biotech Announces Pricing of Up To $18 Million Public Offering
From Purple Biotech Ltd.
Via GlobeNewswire

Performance

YTD
-83.2%
-83.2%
1 Month
-65.1%
-65.1%
3 Month
-71.4%
-71.4%
6 Month
-73.3%
-73.3%
1 Year
-91.9%
-91.9%

More News

Read More
Purple Biotech Announces New Data Supporting the Unique Design of CAPTN-3 Tri-Specific Antibody IM1240 in Collaboration with the Icahn School of Medicine at Mount Sinai
From Purple Biotech Ltd.
Via GlobeNewswire
Which stocks are moving before the opening bell on Wednesday?
Via Chartmill
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
Purple Biotech Expands CAPTN-3 Portfolio with IM1305, a Novel Tri-Specific Antibody Targeting TROP2
From Purple Biotech Ltd.
Via GlobeNewswire
Here are the top movers in Tuesday's session.
Via Chartmill
12 Health Care Stocks Moving In Tuesday's Intraday Session
Via Benzinga
Top movers analysis in the middle of the day on 2025-09-02: top gainers and losers in today's session.
Via Chartmill
Purple Biotech to Participate in the H.C. Wainwright 27th Annual Global Investment Conference
From Purple Biotech Ltd.
Via GlobeNewswire
Purple Biotech CEO Issues Letter to Shareholders Highlighting Pipeline Progress and Clinical Milestones Achieved in First Half of 2025
From Purple Biotech Ltd.
Via GlobeNewswire
Purple Biotech Highlights Significant Advantages of the Novel CAPTN-3 Tri-Specific Antibody Platform at the EACR 2025 Annual Congress
From Purple Biotech Ltd.
Via GlobeNewswire
12 Health Care Stocks Moving In Wednesday's After-Market Session
Via Benzinga
Purple Biotech Announces Initiation of Phase 2 Study of NT219 in Patients with Head and Neck Cancer
From Purple Biotech Ltd.
Via GlobeNewswire
Purple Biotech Announces Poster Presentation at EACR 2025 on its Novel CAPTN-3 Tri-Specific Antibody Platform
From Purple Biotech Ltd.
Via GlobeNewswire
Purple Biotech Appoints Shai Lankry as Chief Financial Officer
From Purple Biotech Ltd.
Via GlobeNewswire
Purple Biotech Reports Final Data from Phase 2 Study of CM24 in Pancreatic Cancer Patients at AACR 2025 Annual Meeting: Improved Outcomes and Significant Efficacy in Biomarker-Enriched Subgroups
From Purple Biotech Ltd.
Via GlobeNewswire
Purple Biotech Reports Positive NT219 Data at AACR for Colorectal and Head and Neck Cancers
From Purple Biotech Ltd.
Via GlobeNewswire
Purple Biotech Announces Publication in the Neuro Oncology Journal Demonstrating the Potential of NT219 to Suppress Brain Metastasis of Colorectal Cancer
From Purple Biotech Ltd.
Via GlobeNewswire
Purple Biotech to Participate in Panel Discussion at Canaccord Genuity Horizons in Oncology Virtual Conference on April 7, 2025
From Purple Biotech Ltd.
Via GlobeNewswire
Purple Biotech Announces Three Posters Accepted for Presentation at the 2025 American Association for Cancer Research Meeting
From Purple Biotech Ltd.
Via GlobeNewswire
Purple Biotech's Shrinking Losses Keep Retail Sentiment In The Green, But Other Pressures Loom
Via Stocktwits
Purple Biotech Granted New U.S. Patent for NT219 in Combination with EGFR Antibody Therapy, Enhancing Global IP Protection in Major Markets
From Purple Biotech Ltd.
Via GlobeNewswire
Purple Biotech Advances NT219 into Phase 2 Head and Neck Cancer Trial
From Purple Biotech Ltd.
Via GlobeNewswire
Purple Biotech Announces Research Collaboration with the Icahn School of Medicine at Mount Sinai for CAPTN-3 Tri-Specific Antibody Platform
From Purple Biotech Ltd.
Via GlobeNewswire

Frequently Asked Questions

Is Purple Biotech Ltd. - American Depositary Shares publicly traded?
Yes, Purple Biotech Ltd. - American Depositary Shares is publicly traded.
What exchange does Purple Biotech Ltd. - American Depositary Shares trade on?
Purple Biotech Ltd. - American Depositary Shares trades on the Nasdaq Stock Market
What is the ticker symbol for Purple Biotech Ltd. - American Depositary Shares?
The ticker symbol for Purple Biotech Ltd. - American Depositary Shares is PPBT on the Nasdaq Stock Market
What is the current price of Purple Biotech Ltd. - American Depositary Shares?
The current price of Purple Biotech Ltd. - American Depositary Shares is 0.7713
When was Purple Biotech Ltd. - American Depositary Shares last traded?
The last trade of Purple Biotech Ltd. - American Depositary Shares was at 09/04/25 11:18 AM ET
What is the market capitalization of Purple Biotech Ltd. - American Depositary Shares?
The market capitalization of Purple Biotech Ltd. - American Depositary Shares is 13.27M
How many shares of Purple Biotech Ltd. - American Depositary Shares are outstanding?
Purple Biotech Ltd. - American Depositary Shares has 13M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.